Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)

• Company Description    Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California. Number of Employees: 242

• Price / Volume Information    Yesterday's Closing Price: $9.98 Daily Weekly Monthly 20 Day Moving Average: 413,389 shares Shares Outstanding: 44.95 (millions) Market Capitalization: $448.60 (millions) Beta: 2.59 52 Week High: $37.43 52 Week Low: $8.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.48% -11.56% 12 Week -39.15% -33.10% Year To Date -65.53% -57.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1700 OWENS STREET SUITE 205 - SAN FRANCISCO,CA 94158 USA ph: 415-660-5320 fax: - lwolffe@wheelhouselsa.com http://www.nurixtx.com

• General Corporate Information    Officers Arthur T. Sands - Chief Executive Officer; President and Director David L. Lacey - Chairman and Director Hans van Houte - Chief Financial Officer Julia P. Gregory - Director Lori A. Kunkel - Director Peer Information Nurix Therapeutics, Inc. (CORR.) Nurix Therapeutics, Inc. (RSPI) Nurix Therapeutics, Inc. (CGXP) Nurix Therapeutics, Inc. (BGEN) Nurix Therapeutics, Inc. (GTBP) Nurix Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67080M103 SIC: 2834 Fiscal Year Fiscal Year End: November Last Reported Quarter: 02/01/22 Next Expected EPS Date: 07/12/22 Share - Related Items Shares Outstanding: 44.95 Most Recent Split Date: (:1) Beta: 2.59 Market Capitalization: $448.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.46 Price/Cash Flow: - Price / Sales: 13.06 EPS Growth vs. Year Ago Period: -50.79% vs. Previous Quarter: -11.76% Sales Growth vs. Year Ago Period: 92.00% vs. Previous Quarter: 30.08% ROE 02/28/22 - -38.11 11/30/21 - -33.83 08/31/21 - -29.81 ROA 02/28/22 - -28.14 11/30/21 - -24.88 08/31/21 - -22.04 Current Ratio 02/28/22 - 4.25 11/30/21 - 4.70 08/31/21 - 7.07 Quick Ratio 02/28/22 - 4.25 11/30/21 - 4.70 08/31/21 - 7.07 Operating Margin 02/28/22 - -394.21 11/30/21 - -393.93 08/31/21 - -342.27 Net Margin 02/28/22 - -394.21 11/30/21 - -393.93 08/31/21 - -342.27 Pre-Tax Margin 02/28/22 - -394.04 11/30/21 - -393.49 08/31/21 - -341.83 Book Value 02/28/22 - 6.82 11/30/21 - 7.67 08/31/21 - 8.45 Inventory Turnover 02/28/22 - - 11/30/21 - - 08/31/21 - - Debt-to-Equity 02/28/22 - 0.00 11/30/21 - 0.00 08/31/21 - 0.00 Debt-to-Capital 02/28/22 - 0.00 11/30/21 - 0.00 08/31/21 - 0.00

Powered by Zacks Investment Research ©